Expression cassette sequence and application thereof
By screening and combining CMV promoter and MSA signal peptides, an expression cassette was designed to solve the problem of low yield of exogenous proteins/polypeptides in mammalian expression systems, achieving efficient expression and secretion, and significantly improving yield.
Patent Information
- Application Number
- CN202310592700.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-24
- Publication Date
- 2024-11-26
AI Technical Summary
In mammalian expression systems, existing signal peptides combined with CMV promoters lead to insufficient yield of exogenous proteins/polypeptides, making it difficult to achieve efficient secretion and expression.
By screening different natural signal peptides and combining CMV promoters, an expression cassette containing MSA signal peptides and CMV promoters significantly improve the yield of target proteins and achieve high yield secretion in host cells.
This expression cassette significantly increases the expression amount of the target gene. Compared with the expression cassette known in the prior art, the expression amount of the target protein is increased by 70%, achieving high yield of exogenous protein/polypeptide secretion.
Smart Images

Figure CN119020407A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to an expression cassette for expressing a target gene, and in particular to an expression cassette comprising a specific promoter and a signal peptide, which can increase the expression amount of the target gene. Background Art
[0002] At present, mammalian cell expression systems have been widely used in the production of a variety of biopharmaceuticals. Mammalian cell expression systems have the functions of post-translational modification and folding in the process of expressing target proteins, making the expressed recombinant proteins closer to natural proteins, and therefore are widely used in the production of biopharmaceuticals. The expressed recombinant proteins are secreted into the culture supernatant of host cells via the secretory pathway in mammalian cells, and then impurities such as host cell proteins are removed through downstream purification processes to obtain high-purity target recombinant proteins. Therefore, in the production process, people have been looking for more effective methods to secrete recombinant proteins into the culture supernatant of host cells with high yield and efficiency.
[0003] Signal peptide is an important component for secretory expression of foreign proteins. Signal peptide is a short peptide chain that guides the newly synthesized protein to the secretory pathway. Usually, the signal peptide is a polypeptide of 15-60 amino acids, located at the N-terminus of the protein. Generally, the gene sequence encoding the target protein is cloned to the C-terminus of the signal peptide, so as to achieve the fusion of the target gene and the signal peptide sequence at the transcription and translation levels in the host cell. The main function of the signal peptide is to promote the secretion of proteins to the extracellular space. In the secretion process of foreign proteins, the signal peptide plays a key role in the secretion amount of foreign proteins.
[0004] The promoter is a DNA sequence located upstream of the transcription region of the target gene that can bind to RNA polymerase to initiate transcription. It is the most critical element for the expression of foreign proteins in host cells and one of the most core elements of the expression vector. Both promoters and signal peptides play an important role in the production of foreign proteins. Therefore, studying different types of signal peptides and finding the best signal peptide after matching with the promoter of the expression vector in the selected host cell is of great significance for achieving efficient expression and secretion of foreign genes.
[0005] Currently, in mammalian expression systems, the human cytomegalovirus (CMV) promoter has become the most widely used expression vector promoter due to its excellent expression effect, and signal peptides are often signal peptides of some natural proteins, such as mouse Ig heavy chain signal peptide, mouse Ig Kappa chain signal peptide, human interleukin 2 (hIL-2) signal peptide, human serum albumin signal peptide, etc. However, after these signal peptides are used in combination with the CMV promoter, there is still a defect that the yield of foreign proteins / peptides is not high enough. Many researchers are trying to develop signal peptides with better yields through methods such as artificial signal peptide research and development and better natural signal peptide screening.
[0006] Therefore, the purpose of the present invention is to screen a large number of natural signal peptides to obtain an effective combination of a signal peptide and a CMV promoter that can improve the expression of a target protein / polypeptide, that is, a new expression cassette, which can secrete the target foreign protein / polypeptide at a high yield when the expression cassette is introduced into a host cell. In addition, another purpose of the present invention is to provide an expression vector that can express a target foreign protein / polypeptide at a high yield, and to provide a method suitable for expressing a target polypeptide at a high yield. Summary of the invention
[0007] The present invention provides an expression cassette for expressing a target protein, wherein the expression cassette comprises a combination of a CMV promoter and a specific signal peptide, and the specific combination significantly increases the yield of the target protein.
[0008] The present invention provides an expression cassette, the expression cassette comprising:
[0009] 1) A promoter, wherein the promoter is a human CMV promoter selected from the group consisting of:
[0010] i) a promoter comprising the sequence shown in SEQ ID NO: 3 or a functional fragment thereof that functions as a promoter;
[0011] ii) comprising a sequence that is at least 80% (preferably at least 85%, more preferably at least 90%, further preferably at least 95%, for example 99%) identical to SEQ ID NO: 3 or a functional fragment thereof that serves as a promoter;
[0012] 2) A signal peptide, wherein the signal peptide is an MSA signal peptide.
[0013] In some embodiments, the expression cassette further comprises:
[0014] 3) 5'UTR polynucleotide sequence (5' untranslated region), and / or
[0015] 4) 3'UTR polynucleotide sequence (3' untranslated region), and / or
[0016] 5) polyA sequence, and / or
[0017] 6) A polynucleotide encoding a target protein or a restriction endonuclease site for inserting a polynucleotide encoding a target protein.
[0018] In some embodiments, the 5'UTR polynucleotide sequence is selected from the group consisting of:
[0019] i) comprising the sequence shown in SEQ ID NO: 6;
[0020] ii) comprising a sequence having at least 80% (preferably at least 85%, more preferably at least 90%, further preferably at least 95%, for example 99%) identity with the sequence shown in SEQ ID NO: 6.
[0021] In some embodiments, the 3'UTR polynucleotide sequence is selected from the group consisting of:
[0022] i) comprising the sequence shown in SEQ ID NO: 7;
[0023] ii) comprises a sequence that is at least 80% (preferably at least 85%, more preferably at least 90%, further preferably at least 95%, such as 99%) identical to SEQ ID NO:7.
[0024] In some embodiments, the sequence of the MSA signal peptide is selected from the group consisting of:
[0025] i) comprising the sequence shown in SEQ ID NO: 1;
[0026] ii) comprising a sequence having at least 80% (preferably at least 85%, more preferably at least 90%, further preferably at least 95%, for example 99%) identity with the sequence shown in SEQ ID NO: 1.
[0027] In some embodiments, the polyA sequence is selected from the polyA sequence of SV40.
[0028] In some embodiments, the sequence of the polyA is shown as SEQ ID NO:5.
[0029] In some embodiments, the sequence of the polyA is selected from the group consisting of:
[0030] i) comprising the sequence shown in SEQ ID NO: 5;
[0031] ii) comprising a sequence having at least 80% (preferably at least 85%, more preferably at least 90%, further preferably at least 95%, for example 99%) identity with the sequence shown in SEQ ID NO:5.
[0032] In some embodiments, the promoter is located at the 5' end of the signal peptide sequence, the signal peptide sequence is linked to the polynucleotide encoding the target protein, the signal peptide sequence is located at the N-terminus, and the poly A sequence is located at the 3' end of the target gene.
[0033] In some embodiments, the polynucleotide encoding the target protein in the expression cassette expresses an Fc fusion protein.
[0034] In some embodiments, the polynucleotide encoding the target protein in the expression cassette expresses an antibody or a functional fragment thereof.
[0035] In some embodiments, the polynucleotide encoding the target protein in the expression cassette expresses a VHH antibody or a functional fragment thereof.
[0036] In some embodiments, the polynucleotide encoding the target protein in the expression cassette expresses the Aflibercept protein.
[0037] In some embodiments, the sequence of the Aflibercept protein is as shown in SEQ ID NO:4.
[0038] The present invention also provides a plasmid comprising the above expression cassette.
[0039] The present invention also provides a host cell comprising the above plasmid or expression cassette.
[0040] In some embodiments, the host cell is selected from CHO cells, preferably suspension-educated CHO cells.
[0041] The present invention also provides the use of the above expression cassette, plasmid or host cell in expressing a target gene.
[0042] The present invention provides the use of the above expression cassette, plasmid or host cell in preparing target protein.
[0043] The present invention also provides a method for preparing a target protein, which comprises culturing the above host cell in a cell culture manner under conditions that allow the expression of the target protein.
[0044] Beneficial Effects
[0045] The present invention obtains an effective combination of a signal peptide and a CMV promoter that can improve the expression of a target protein by screening a signal peptide. When the expression cassette is introduced into a host cell, it can secrete a target exogenous protein / polypeptide at a high yield. The expression cassette of the present invention greatly increases the expression amount of the target gene. The expression cassette of the present invention is superior to the expression cassette known in the prior art, and the expression amount of the target protein is increased by 70%. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1 The element pattern of the expression cassette in some embodiments of the present invention is shown;
[0047] Figure 2 The expression levels of target proteins of expression cassettes constructed with different signal peptides in Example 1 of the present invention are shown;
[0048] Figure 3 The expression levels of target proteins of different expression cassette sequences in Example 2 of the present invention are shown. DETAILED DESCRIPTION
[0049] The term "expression cassette" as used herein refers in particular to a DNA segment that, under appropriate settings, can drive the expression of a polynucleotide encoding a target polypeptide bound to the expression cassette. When introduced into a host cell, the expression cassette can in particular direct the cellular machinery to transcribe the bound polynucleotide encoding the target polypeptide into RNA, which is then typically further processed and ultimately translated into the target polypeptide. As further described below, the expression cassette can be included in an expression vector. The various elements of the expression cassette of the present invention are described in detail later.
[0050] The technical scheme of the present invention is further described in detail below by examples and in conjunction with the accompanying drawings. Unless otherwise specified, the methods and materials of the embodiments described below are conventional products that can be purchased from the market. It will be understood by those skilled in the art that the present invention belongs to that the methods and materials described below are only exemplary and should not be considered as limiting the scope of the present invention.
[0051] Embodiment 1:
[0052] Expression cassettes of signal peptides from different sources were screened, different stable cell pools were constructed using the expression cassettes, and batch feeding experiments were performed to express the Fc fusion protein Aflibercept (VEGF-Trap), thereby obtaining the protein yield of expression cassettes containing different signal peptides. This example shows the experimental results of 11 signal peptides as shown in Table 1.
[0053] Aflibercept is an FDA-approved intravitreal injection drug for the treatment of neovascular age-related macular degeneration and macular edema caused by central retinal vein occlusion. It is an anti-vascular endothelial growth factor ophthalmic drug.
[0054] Table 1
[0055]
[0056]
[0057] Specifically, the following steps are included:
[0058] Step 1, construct expression vectors containing different signal peptide expression cassettes, the vector is pcDNA3.1, synthesized by GenScript Biotech Co., Ltd. The screening gene on the expression vector is changed to glutamine synthetase (GS) screening gene (SEQ ID NO: 10), and the Aflibercept gene (SEQ ID NO: 4) is cloned into expression plasmids containing different expression cassettes.
[0059] The promoter is selected from human CMV, and the sequence is shown in SEQ ID NO: 3; the sequence of 5'UTR is shown in SEQ ID NO: 6; the sequence of 3'UTR is shown in SEQ ID NO: 7; and the polyA is selected from the polyA of SV40, and the sequence is shown in SEQ ID NO: 5.
[0060] Step 2: The plasmid constructed in step 1 was electro-transfected into CHOK1 cells (purchased from ECACC) at a rate of 30 μg per group to obtain transfected cells. TM ), electroporation parameters: 250 V, 30 ms, 4 mm square wave. On the day of transfection, the host cell density was between 1E6-4E6 cells / ml, and the viability was greater than 90%.
[0061] 1E7 cells were transfected with different plasmids, and the volume of cell suspension required for each transfection was calculated according to the density. The cell suspension was centrifuged (1500 rpm, 10 min), the supernatant was discarded, and the cells were resuspended in 200 μl CDCHO culture medium (ThermoFisher, catalog number: 10743029) for each group.
[0062] Step 3, 48 hours after transfection, add screening medium containing MSX (CDCHO + 20μM MSX, MSX: Sigma-Aldrich, catalog number: m5379) to the transfected cells, resuspend at a density of 1-2E5 cells / ml, plate in a 24-well plate, place 0.5 ml of cell suspension in each well, perform small cell pool screening, replace fresh screening medium every 4 to 6 days, and observe the cell state under a microscope before changing the medium;
[0063] Step 4, when more than 1 / 3 of the cells in the small cell pool in the 24-well plate adapt to the screening pressure and the cells return to normal proliferation state (compared with the last observation under the microscope, the total number of cells increases and the viability improves), a stable cell pool is obtained, and the supernatant is collected. The expression level of the 24-well plate cell pool is detected by Elisa method, Elisa coating antibody (sheep anti-human IgG-UNLB, Southern Biotech, catalog number: 2040-01), Elisa detection antibody (sheep anti-human IgG Fc cross-adsorption secondary antibody, HRP, ThermoFisher, catalog number: 31413).
[0064] Step 5, select 10-12 small cell pools with the highest expression level from each group of cells, expand the selected small cell pools from the 24-well plate to the 6-well plate, and when the cell viability of all small cell pools recovers to about 90%, dilute the cells at a uniform density (0.4E6 cells / ml) into the Dynamis medium (ThermoFisher, catalog number: A2661501) used in production, and place the cells in a shaker.
[0065] Step 6: Perform fed-batch culture on the cell pools, feed them once every 2 days, and use the feed medium (EfficientFeed TM B+3X Supplement, ThermoFisher, Catalog No.: A3937501), the feed volume is 4% of the volume of the basal medium.
[0066] Step 7: After 14 days, the supernatant of the fed-batch culture of the cell pools was collected, and the protein expression level of each cell pool was detected by Elisa method.
[0067] The experimental results are as follows Figure 2 The protein expression obtained by the plasmid containing the mouse MSA signal peptide and the human hcd33 signal peptide HCD33 was significantly higher than that of other plasmids. Compared with the plasmid containing the mouse Ig Kappa light chain signal peptide (MIGK), the average production of Aflibercept in the MSA cell pool increased by 70%, and that in the HCD33 cell pool increased by 60% (the average production of the MIGK cell pool was 435±56mg / L, the average production of the MSA cell pool was 755±69mg / L, and the average production of the HCD33 cell pool was 702±45mg / L).
[0068] Embodiment 2:
[0069] This example compares expression cassettes containing three different signal peptides (MSA, HCD33, MIGK), constructs different stable cell pools with these three expression cassettes, and performs batch feeding experiments to express Fc fusion protein #1, thereby obtaining the protein yield of expression cassettes containing different signal peptides. Specifically, the following steps are included:
[0070] Step 1, construct expression vectors containing three different signal peptide expression cassettes, the vector is pcDNA3.1, synthesized by GenScript Biotech Co., Ltd. The screening gene on the expression vector is the glutamine synthetase (GS) screening gene, and the gene of the Fc fusion protein is cloned into the three expression plasmids respectively.
[0071] The promoter is selected from human CMV, and the sequence is shown in SEQ ID NO: 3; the sequence of 5'UTR is shown in SEQ ID NO: 6; the sequence of 3'UTR is shown in SEQ ID NO: 7; and the polyA is selected from the polyA of SV40, and the sequence is shown in SEQ ID NO: 5.
[0072] Step 2, the plasmid constructed by the method of step 1 is introduced into CHOK1 cells (purchased from ECACC) by electroporation. On the day of transfection, the host cell density is between 1E6-4E6 cells / ml, and the viability is greater than 90%.
[0073] Take 3 groups of transfected cells, each transfection requires 1E7 cells, calculate the volume of cell suspension required for each transfection according to the density, centrifuge the cell suspension (1500 rpm, 10 minutes), discard the supernatant, and resuspend the cells in 200 μl CDCHO culture medium (ThermoFisher, catalog number: 10743029).
[0074] Take 30 μg of each of the three plasmids in step 1, add them to the prepared cell suspension and mix well, then perform electrotransfection. Transfect cells with an electroporator (Bio-Rad, Gene Pulser Xcell TM ), electroporation parameters: 250 V, 30 ms, 4 mm square wave.
[0075] Step 3, 48 hours after transfection, add screening medium containing MSX (CDCHO + 20μM MSX, MSX: Sigma-Aldrich, catalog number: m5379) to the transfected cells, resuspend at a density of 1-2E5 cells / ml, plate in a 24-well plate, place 0.5 ml of cell suspension in each well, perform small cell pool screening, replace fresh screening medium every 4 to 6 days, and observe the cell state under a microscope before changing the medium;
[0076] Step 4. When more than 1 / 3 of the cells in the small cell pool in the 24-well plate adapt to the screening pressure and the cells return to normal proliferation (compared with the last observation under the microscope, the total number of cells increases and the viability improves), a stable cell pool is obtained, the supernatant is collected, and the expression level of the 24-well plate cell pool is detected by Elisa method, Elisa coating antibody (Goat anti Human IgG-UNLB, Southern Biotech, catalog number: 2040-01), Elisa detection antibody (Goat anti-Human IgG FcCross-Adsorbed Secondary Antibody, HRP, ThermoFisher, catalog number: 31413).
[0077] Step 5, select 10-12 small cell pools with the highest expression level from each group of cells, expand the selected small cell pools from the 24-well plate to the 6-well plate, and when the cell viability of all small cell pools recovers to about 90%, dilute the cells at a uniform density (0.4E6 cells / ml) into the Dynamis medium (ThermoFisher, catalog number: A2661501) used in production, and place the cells in a shaker.
[0078] Step 6: Perform fed-batch culture on the cell pools, feed them once every 2 days, and use the feed medium (EfficientFeed TM B+3X Supplement, ThermoFisher, Catalog No.: A3937501), the feed volume was 4% of the volume of the basal medium.
[0079] Step 7: After 14 days, the supernatant of the fed-batch culture of the cell pools was collected, and the protein expression level of each cell pool was detected by Elisa method.
[0080] The experimental results are as follows Figure 3 As shown. The protein expression levels obtained by plasmids containing mouse serum albumin signal peptide (MSA) and human hcd33 protein signal peptide (HCD33) were significantly higher than those obtained by MIGK plasmids. Compared with the plasmid (MIGK) containing the commonly used mouse Ig Kappa light chain signal peptide, the average protein yield of the MSA cell pool increased by 50%, and the average protein yield of the HCD33 cell pool increased by 69% (the average yield of the MIGK cell pool was 13.4±4.5mg / L, the average yield of the MSA cell pool was 20.6±6.1mg / L, and the average yield of the HCD33 cell pool was 22.7±3.9mg / L).
[0081] The implementation of the present invention is not limited to the above-mentioned embodiments. Without departing from the spirit and scope of the present invention, ordinary technicians in this field can make various changes and improvements to the present invention in form and detail, and these are considered to fall within the protection scope of the present invention.
[0082] The sequence information is as follows:
[0083] SEQ ID NO 1 (mouse serum albumin signal peptide): MKWVTFLLLLFVSGSAFS
[0084] SEQ ID NO 2 (human hcd33 protein signal peptide): MPLLLLLPLLWAGALA
[0085] SEQ ID NO 3 (CMV promoter):
[0086] gacattgattattgactagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatgg
[0087] cccgcctggctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtc
[0088] aatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat
[0089] ggcccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcgg
[0090] ttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcacc
[0091] aaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcag
[0092] agct
[0093] SEQ ID NO 4(Aflibercept):
[0094] SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
[0095] SEQ ID NO 5 (SV40 polyA sequence):
[0096] AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCAC
[0097] AAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATC
[0098] TTA
[0099] SEQ ID NO 6 (5’UTR):
[0100] CTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAAT
[0101] SEQ ID NO 7 (3’UTR):
[0102] GCCGAGGAGCAGGACTGACTACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCC
[0103] SEQ ID NO 8 (mouse chymotrypsinogen B signal peptide): MAFLWLVSCFALVGATFG
[0104] SEQ ID NO 9 (human chymotrypsinogen signal peptide): MAFLWLLSCWALLGTTFG
[0105] SEQ ID NO 10 (human serum albumin signal peptide): MKWVTFISLLFLFSSAYS
[0106] SEQ ID NO 11 (human IL-2 signal peptide): MYRMQLLSCIALSLALVTNS
[0107] SEQ ID NO 12 (human protease activated receptor 2 signal peptide): MRSPSAAWLLGAAILLAASLSCSG SEQ ID NO 13 (Secrecon signal peptide): MWWRLWWLLLLLLLLWPMVWA
[0108] SEQ ID NO 14 (Secrecon+AA signal peptide): MWWRLWWLLLLLLLLWPMVWA+AA
[0109] SEQ ID NO 15 (mouse Ig heavy chain (Heavy) signal peptide): MGWSCIILFLVATATGVHS
[0110] SEQ ID NO 16 (mouse Ig Kappa signal peptide): METDTLLLWVLLLWVPGSTG.
Claims
1. An expression cassette, comprising: 1) A promoter, wherein the promoter is a human CMV promoter selected from the group consisting of: i) a promoter comprising the sequence shown in SEQ ID NO: 3 or a functional fragment thereof that functions as a promoter; ii) comprising a sequence that is at least 80% (preferably at least 85%, more preferably at least 90%, further preferably at least 95%, for example 99%) identical to SEQ ID NO: 3 or a functional fragment thereof that serves as a promoter; 2) A signal peptide, wherein the signal peptide is an MSA signal peptide.
2. The expression cassette according to claim 1, characterized in that The sequence of the MSA signal peptide is selected from the group consisting of: i) comprising the sequence shown in SEQ ID NO: 1; ii) comprising a sequence having at least 80% (preferably at least 85%, more preferably at least 90%, further preferably at least 95%, for example 99%) identity with the sequence shown in SEQ ID NO:
1.
3. The expression cassette according to claim 1 or 2, characterized in that The expression cassette further comprises: 3) 5'UTR polynucleotide sequence (5' untranslated region); Preferably, the expression cassette further comprises: 4) 3'UTR polynucleotide sequence (3' untranslated region); Preferably, the expression cassette further comprises: 5) polyA sequence; Preferably, the expression cassette further comprises: 6) A polynucleotide encoding a target protein or a restriction endonuclease site for inserting a polynucleotide encoding a target protein.
4. The expression cassette according to claim 3, characterized in that The 5'UTR polynucleotide sequence is selected from the group consisting of: i) comprising the sequence shown in SEQ ID NO: 6; ii) comprising a sequence having at least 80% (preferably at least 85%, more preferably at least 90%, further preferably at least 95%, for example 99%) identity with the sequence shown in SEQ ID NO: 6; Preferably, the 3'UTR polynucleotide sequence is selected from the group consisting of: i) comprising the sequence shown in SEQ ID NO: 7; ii) comprises a sequence that is at least 80% (preferably at least 85%, more preferably at least 90%, further preferably at least 95%, for example 99%) identical to SEQ ID NO: 7; Preferably, the polyA sequence is selected from the group consisting of: i) comprising the sequence shown in SEQ ID NO: 5; ii) comprising a sequence having at least 80% (preferably at least 85%, more preferably at least 90%, further preferably at least 95%, for example 99%) identity with the sequence shown in SEQ ID NO:
5.
5. The expression cassette according to any one of claims 1 to 4, characterized in that The promoter is located at the 5' end of the signal peptide sequence, the signal peptide sequence is connected to the polynucleotide encoding the target protein, the signal peptide sequence is located at the N-terminus, and the poly A sequence is located at the 3' end of the target gene.
6. The expression cassette according to any one of claims 1 to 5, characterized in that The polynucleotide encoding the target protein in the expression cassette expresses an Fc fusion protein, an antibody or a functional fragment thereof; Preferably, the Fc fusion protein is Aflibercept protein; the sequence of Aflibercept protein is preferably as shown in SEQ ID NO:
4.
7. A plasmid comprising the expression cassette of any one of claims 1 to 6.
8. A host cell comprising the expression cassette of any one of claims 1 to 6 or the plasmid of claim 7; Preferably, the host cell is selected from CHO cells, preferably suspension-cultured CHO cells.
9. Use of the expression cassette according to any one of claims 1 to 6, the plasmid according to claim 7 or the host cell according to claim 8 in expressing a target gene or target protein.
10. A method for preparing a target protein, the method comprising culturing the host cell according to claim 8 in a cell culture manner under conditions that allow the expression of the target protein.
